Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia

Marie Emilie Dourthe^{1

2}, Karima Yakouben¹, Audrey David³, Sandrine Thouvenin³, Delphine Chaillou¹, Sophie Caillat-Zucman⁴, Alexis Cuffel⁴, Cléa Tardy⁵, Elodie Lainey⁶, Aurélie Caye-Eude^{7

8}, Chloé Arfeuille^{7

8}, Constance Delaugerre⁹, Marie-Laure Chaix-Baudier⁹, Jérôme Naudin¹⁰, Stéphane Auvin¹¹, Karim Bergaoui¹², Anne-Isabelle Merlat-Guitard¹³, Romain De Jorna¹⁴, Miryam Mebarki¹⁵, Jean-Hugues Dalle¹, André Baruchel^{1

16}

Affiliations

¹ Department of Pediatric Hematology and Immunology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
² Laboratory of Onco-Hematology, Hôpital Necker Enfants-Malades, AP-HP and Université Paris Cité, Institut Necker-Enfants Malades (INEM), INSERM U1151, Paris, France.
³ Department of Pediatric Hematology and Oncology, Centre Hospitalier Universitaire de Saint Etienne, Saint Etienne, France.
⁴ Laboratory of Immunology, Hôpital Universitaire Saint Louis, AP-HP and INSERM UMR1149, Université Paris Cité, Paris, France.
⁵ Pharmacy Department, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
⁶ Laboratory of Hematology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
⁷ Department of Genetics, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
⁸ INSERM U1131, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.
⁹ Laboratory of Virology, Hôpital Saint Louis, AP-HP and Université Paris Cité, Paris, France.
¹⁰ Pediatric Intensive Care Unit, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
¹¹ Neurology Department, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
¹² Radiology Department, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
¹³ Novartis Pharma S.A.S., Rueil-Malmaison, France.
¹⁴ Pharmacy Department, Hôpital Saint Louis, AP-HP and Université Paris Cité, Paris, France.
¹⁵ Unité de Thérapie Cellulaire et Centre MEARY de Thérapie Cellulaire et Génique, AP-HP and Université Paris Cité, Hôpital Saint- Louis, U976 et CICBT, INSERM, Paris, France.
¹⁶ EA3518, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.

PMID: 38735758
DOI: 10.1111/bjh.19524

Case Reports

Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia

Marie Emilie Dourthe et al. Br J Haematol. 2024 Jul.

. 2024 Jul;205(1):373-377.

doi: 10.1111/bjh.19524. Epub 2024 May 12.

Authors

Affiliations

¹ Department of Pediatric Hematology and Immunology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
² Laboratory of Onco-Hematology, Hôpital Necker Enfants-Malades, AP-HP and Université Paris Cité, Institut Necker-Enfants Malades (INEM), INSERM U1151, Paris, France.
³ Department of Pediatric Hematology and Oncology, Centre Hospitalier Universitaire de Saint Etienne, Saint Etienne, France.
⁴ Laboratory of Immunology, Hôpital Universitaire Saint Louis, AP-HP and INSERM UMR1149, Université Paris Cité, Paris, France.
⁵ Pharmacy Department, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
⁶ Laboratory of Hematology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
⁷ Department of Genetics, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
⁸ INSERM U1131, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.
⁹ Laboratory of Virology, Hôpital Saint Louis, AP-HP and Université Paris Cité, Paris, France.
¹⁰ Pediatric Intensive Care Unit, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
¹¹ Neurology Department, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
¹² Radiology Department, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
¹³ Novartis Pharma S.A.S., Rueil-Malmaison, France.
¹⁴ Pharmacy Department, Hôpital Saint Louis, AP-HP and Université Paris Cité, Paris, France.
¹⁵ Unité de Thérapie Cellulaire et Centre MEARY de Thérapie Cellulaire et Génique, AP-HP and Université Paris Cité, Hôpital Saint- Louis, U976 et CICBT, INSERM, Paris, France.
¹⁶ EA3518, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.

PMID: 38735758
DOI: 10.1111/bjh.19524

No abstract available

PubMed Disclaimer

References

REFERENCES

1. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B‐cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.
1. Laetsch TW, Maude SL, Rives S, Hiramatsu H,Bittencourt H,Bader P, et al. Three‐year update of Tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664–1169.
1. Grupp SA, Maude SL, Rives S, Baruchel A, Boyer MW, Bittencourt H, et al. Updated analysis of the efficacy and safety of Tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia. Blood. 2018;132(Supplement 1):895.
1. Schultz LM, Baggott C, Prabhu S, Pacenta H, Phillips CL, Rossoff J, et al. Disease burden impacts outcomes in pediatric and young adult B‐cell acute lymphoblastic leukemia after commercial Tisagenlecleucel: results from the pediatric real world CAR consortium (PRWCC). Blood. 2020;136(Supplement 1):14–15.
1. Dourthe M‐E, Rabian F, Yakouben K, Chevillon F, Cabannes‐Hamy A, Méchinaud F, et al. Determinants of CD19‐positive vs CD19‐negative relapse after tisagenlecleucel for B‐cell acute lymphoblastic leukemia. Leukemia. 2021;35(12):3383–3393.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia

Affiliations

Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia

Authors

Affiliations

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources